Make GLP‑1 coverage affordable — today and tomorrow
This employer guide gives you the data and care strategy to make GLP-1 coverage financially sustainable. Learn how to cut GLP-1 spending by up to 50% while delivering long-term health outcomes.
Based on leading GLP-1 real-word study
Must-read for benefit leaders
Proven model to make GLP-1 coverage ROI-positive
What's inside
Why most GLP-1 programs are overmedicating (and overspending)
How Embla achieved clinical trial-level outcomes (with less than half the medication)
The difference between fixed-dose vs. treat-to-target GLP-1 prescribing
How outcomes held steady across BMI groups and semaglutide doses
The role behavioral care plays in sustainable weight loss
What this means for benefit design, plan costs, and long-term GLP-1 access
Based on top GLP-1 study showing better outcomes at lower doses
The TRIM study, presented by the Embla research team at ECO 2025, followed 2,694 adults over 64 weeks and found an average weight loss of 16.7% — using less than half the typical semaglutide dose.
Nearly 80% successfully tapered or stopped medication. Results were consistent across BMI groups, dose levels, and demographics, showing what’s possible with a behavior-first, coaching-led model.
Get the GLP-1 playbook today
A must-read for:
HR and benefits leaders navigating GLP-1 demand and rising claims
Brokers and consultants looking for evidence-based, cost-controlled solutions
Clinical teams exploring sustainable models for medication tapering
Finance leaders focused on long-term cost containment and ROI